Ipsen re­turns to Maren­go Ther­a­peu­tics for new trispe­cif­ic deal

Ipsen and Maren­go Ther­a­peu­tics are ex­pand­ing a deal to in­clude two trispe­cif­ic an­ti­body as­sets that tack­le so-called cold tu­mors, which do not typ­i­cal­ly re­spond well …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER